Multi-omics molecular phenotyping reveals the potential mechanisms of chemotherapy response and resistance in small cell lung cancer

Ying Cheng; Jie Hu; Xuan Gao; Bingfa Yan; Zelong Xu; Ying Liu; Jing Zhu; Zhentian Liu; Ying Wang; Junfeng Wang; Ying Xin; Ke Zheng; Yawen Yang; Xuefeng Xia; Xin Yi; Kai Niu; Changliang Yang; Hongxia Cui; Yanrong Wang; Guang Yang; Jie Hao; Peidong Li; Liang Zhang; Zili Li; Hongyu Wang; Yanli Sun; Shubo Zuo; Tianying Du; Jinhua Xu; Gan Zhang; Fei Chen; Ning Ding

doi:10.1002/ctm2.1728

Clinical and Translational Medicine ›› 2024, Vol. 14 ›› Issue (6) : e1728 DOI: 10.1002/ctm2.1728

LETTER TO THE JOURNAL

Multi-omics molecular phenotyping reveals the potential mechanisms of chemotherapy response and resistance in small cell lung cancer

Author information +

History +

PDF

Cite this article

Download citation ▾

Ying Cheng, Jie Hu, Xuan Gao, Bingfa Yan, Zelong Xu, Ying Liu, Jing Zhu, Zhentian Liu, Ying Wang, Junfeng Wang, Ying Xin, Ke Zheng, Yawen Yang, Xuefeng Xia, Xin Yi, Kai Niu, Changliang Yang, Hongxia Cui, Yanrong Wang, Guang Yang, Jie Hao, Peidong Li, Liang Zhang, Zili Li, Hongyu Wang, Yanli Sun, Shubo Zuo, Tianying Du, Jinhua Xu, Gan Zhang, Fei Chen, Ning Ding. Multi-omics molecular phenotyping reveals the potential mechanisms of chemotherapy response and resistance in small cell lung cancer. Clinical and Translational Medicine, 2024, 14(6): e1728 DOI:10.1002/ctm2.1728

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Gazdar AF, Bunn PA, Minna JD. Small-cell lung cancer: what we know, what we need to know and the path forward. Nat Rev Cancer. 2017;17:725-737.

[2]	Sabari JK, Lok BH, Laird JH, Poirier JT, Rudin CM. Unravelling the biology of SCLC: implications for therapy. Nat Rev Clin Oncol. 2017;14:549-561.

[3]	Bunn PA, Minna JD, Augustyn A, et al. Small cell lung cancer: can recent advances in biology and molecular biology be translated into improved outcomes? J Thorac Oncol. 2016;11:453-474.

[4]	Cullis J, Das S, Bar-Sagi D. Kras and tumor immunity: friend or foe? Cold Spring Harb Perspect Med. 2018;8:a031849.

[5]	Yi Z, Ma F, Rong G, et al. The molecular tumor burden index as a response evaluation criterion in breast cancer. Signal Transduct Target Ther. 2021;6:251.

[6]	Horn L, Mansfield AS, Szczesna A, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379:2220-2229.

[7]	Gay CM, Stewart CA, Park EM, et al. Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell. 2021;39:346-360. e347.

[8]	Slominski RM, Raman C, Chen JY, Slominski AT. How cancer hijacks the body's homeostasis through the neuroendocrine system. Trends Neurosci. 2023;46:263-275.

RIGHTS & PERMISSIONS

2024 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.